Reduced intensity (RI) allogeneic stem cell transplantation (AlloSCT) was initially demonstrated in adults following HLA-matched family and unrelated adult donor AlloSCT. There is little information about RI AlloSCT in children. We report results of a pilot study of RI AlloSCT in 21 recipients (p21 years). Age: median 13 (0.5-21) years, 8F:13M, 14 unrelated cord blood units (UCB) (10 4/6, 4 5/6), two related BM (6/6, 5/6), four related PBSC (2 6/6, 2 5/6), and one related BM þ PBSC (6/6). RI: fludarabine, busulfan (n ¼ 14); fludarabine, cyclophosphamide (n ¼ 4); fludarabine, melphalan (n ¼ 1); total body irradiation, fludarabine, cyclophosphamide (n ¼ 1); or fludarabine, cyclophosphamide, and etoposide (n ¼ 1). Graft-versus-host disease prophylaxis: FK506 0.03 mg/ kg/day and mycophenolate mofetil 15 mg/kg/q 12 h. UCB median nuc/kg and CD34/kg was 4.3 Â 10 7 /kg (0.9-10.8) and 1.9 Â 10 5 /kg (0.3-6.9), and related BM/PBSC median nuc/kg and CD34/kg was 8.3 Â 10 8 (4.7-18.9) and 5.0 Â 10 6 /kg (4.6-6.4). Maximal chimerism following unrelated cord blood transplantation, 100% Â 7, 98% Â 1, 95% Â 2, 55% Â 1, and 0% Â 3; related PBSC/BM, 100% Â 5, 65% Â 1, and 55% Â 1. Graft failure occurred in 5/21 (24%). In summary, RI AlloSCT in children is feasible and tolerable (p25% GF) and results in X85% of recipients initially achieving X50% donor chimerism. (2004) We and others have previously demonstrated that unrelated cord blood can be used successfully as an alternative allogeneic stem cell source and safely reconstitute HLA 2 to 3 antigen disparate recipients (children and adults) with both malignant and nonmalignant diseases.
lical cord blood; chimerism
We and others have previously demonstrated that unrelated cord blood can be used successfully as an alternative allogeneic stem cell source and safely reconstitute HLA 2 to 3 antigen disparate recipients (children and adults) with both malignant and nonmalignant diseases. [1] [2] [3] [4] [5] [6] [7] Unfortunately, one of the limitations of unrelated cord blood transplantation (UCBT) is a significantly reduced cell dose (0.3-0.5 Â 10 8 nucleated cell/kg) that results in delayed median time to myeloid engraftment (24-28 days) compared to other mobilized allogeneic stem cell donors. [1] [2] [3] [4] [5] [6] [7] However, there is still a significant incidence of serious morbidity and mortality following myeloablative therapy and UCBT. Rubinstein et al 5 previously reported the outcome of the first 562 recipients of myeloablative UCBT from cord blood units transplanted from the New York Blood Center and demonstrated 218 deaths during the first 100 days post UCBT secondary to either infection (47%), pulmonary toxicity (26%), multiorgan system failure (12%), graft-versus-host disease (GVHD) (11%), and veno-occlusive disease of the liver (7%). Similarly, Gluckman et al 7 reported the results of 65 patients who were recipients of myeloablative UCBT from the Eurocord Transplant Group and demonstrated 38 deaths (58%) due to primary causes of infection (26%), pulmonary (24%), veno-occlusive disease (10%), GVHD (10%), cardiac (5%), and other toxicities.
Several years ago, Storb et al 8 originally demonstrated the ability to achieve mixed and ultimately complete donor chimerism following reduced-intensity (RI) conditioning (200 cGy) in DLA-identical canine allogeneic transplant recipients and subsequently demonstrated the successful ability to administer donor lymphocyte infusions (DLI) as potential adoptive cellular immunotherapy following RI conditioning in a similar animal model. 9 Slavin et al 10 subsequently demonstrated that utilizing a fludarabinebased RI conditioning regimen (fludarabine, busulfan, and antithymocyte globulin (ATG)) followed by HLA-matched family donor (MFD) allogeneic stem cell transplantation (AlloSCT) resulted in complete donor chimerism in adults with poor-risk hematological malignancies. Additional studies have substantiated the ability to induce mixed/ complete donor chimerism in a significant number of adult recipients with poor-risk hematological malignancies and solid tumors (renal cancer) following RI conditioning and allogeneic HLA-MFD SCT. [11] [12] [13] [14] [15] [16] [17] More recently, several investigators have demonstrated the ability to successfully induce complete donor chimerism following RI conditioning and AlloSCT from matched unrelated adult donors. [18] [19] [20] [21] There is limited data regarding RI conditioning and AlloSCT in children and adolescents. 22 Myeloablative conditioning prior to SCT is limited in large part by a significant incidence of short-term toxicity and late effects. It is unknown whether RI conditioning in children will result in a decrease in long-term late effects and not be associated with increased graft failure and/or disease reoccurrence. We hypothesize that RI AlloSCT in children will be well tolerated and result in rapid neutrophil and platelet recovery and greater than 50% stable mixed donor chimerism. In this report, we report the preliminary results, including donor chimerism, toxicity, engraftment, GVHD, infection, and survival, in a group of 21 heterogenous children and adolescents with either malignant or nonmalignant disorders who received RI conditioning followed by either UCBT or matched family donor AlloSCT.
Materials and methods

Eligibility
Patients o21 years of age with both malignant and nonmalignant disorders were eligible for RI conditioning followed by AlloSCT if they met specific RI AlloSCT protocol eligibility requirements (Table 1) . Patients were eligible if they had a fully HLA-MFD or a one-antigen HLA-mismatched family donor or a matched one-or twoantigen-mismatched unrelated cord blood unit with a minimum of 1.5 Â 10 7 nucleated cells/kg. All patients required a 450% Lansky (o16 years) or Karnofsky (416 years) performance status prior to study entry. All patients signed informed consents approved by the Institutional Review Board of Columbia Presbyterian Medical Center and all research protocols were in compliance with the Declaration of Helsinki.
Reduced conditioning regimen
All patients received a fludarabine-based reduced conditioning regimen. Patients were enrolled on one of seven RI AlloSCT IRB approved protocols. The patients with recurrent/refractory lymphoma received a RI AlloSCT following a myeloablative AutoSCT as per protocol. A total of 11 patients received fludarabine (150 mg/m Table 1) .
AlloSCT
Recipients of HLA-MFDs received filgrastim-stimulated peripheral blood using standard apheresis procedures or filgrastim-stimulated allogeneic bone marrow using standard bone marrow harvesting procedures following a dose of filgrastim (10 mcg/kg/day) for 4 days with collection by either apheresis or bone marrow harvest on the fifth day for a minimum target dose of 5.0 Â 10 6 CD34 þ cells/kg/ recipient body weight. Recipients of progenitor cells from unrelated cord blood donors received thawed unrelated cord blood progenitor cells following our previously described methods and those of Rubinstein et al.
23,24
GVHD prophylaxis
Acute GVHD prophylaxis consisted of tacrolimus (FK506) starting at 0.03 mg/kg/day as continuous intravenous infusion with dosage adjustment to maintain blood levels between 5.0 and 20 ng/ml and mycophenolate mofetil (MMF) at 15 mg/kg/q 6-12 h either orally or intravenously as we have previously described. 25 Tacrolimus was started either on day À1 or day À7 and MMF was begun on day þ 1. GVHD prophylactic medications were maintained for a minimum of 30 days post AlloSCT. Tacrolimus and/or MMF were tapered if patients had pgrade II acute GVHD sometime between day þ 30 and day þ 90. 25 
Supportive care
Hematopoietic growth factor support, isolation, antibacterial, antifungal, and antiviral prophylaxis were performed according to institutional protocols. Briefly, all patients received sarmograstim (GM-CSF) (250 mcg/m 2 /day) intravenously daily from day 0 until the WBC reached X0.3 Â 2 days and then were switched to G-CSF either intravenously or subcutaneously at 10 mcg/kg/day until an absolute neutrophil count (ANC) of X2.5 Â 10 9 /l was achieved for 3 days. Packed red blood cells were transfused to maintain hemoglobin levels of 8.0 gm/dl or more and platelets were transfused to keep the platelet count at 20 Â 10 9 /l or greater. All blood products were filtered and irradiated to 1500 cGy. Herpes simplex prophylaxis consisted of acyclovir (250 mg/m 2 ) intravenously q 8 h from day À5 until engraftment and pgrade II mucositis. Pneumocystis carinii prophylaxis consisted of trimethoprim/sulfamethoxazole until day À1 and then resumed three times weekly after myeloid engraftment (ANC X500/mm 3 Â 2 days). Patients unable to tolerate trimethoprim/sulfamethoxazole received q 2-4 weeks pentamidine (intravenous) prophylaxis. Fungal prophylaxis consisted of liposomal amphotericin B (3.0 mg/kg/day) intravenously starting on day 0 through day þ 100 as we previously described. 26 CMV prophylaxis for CMV-negative donor and recipient consisted of CMV-negative blood products only. CMV prophylaxis for recipients that were either CMV serologically positive and/or donor positive was alternating doses of ganciclovir (5.0 mg/kg/day) intravenously and foscarnet (90 mg/kg/day) intravenously starting at ANC X750/ mm 3 Â 2 days through day þ 100 as we previously described. 27 Engraftment, chimerism, and HLA typing Myeloid engraftment (neutrophil recovery) was defined as an ANC of X0.5 Â 10 9 /l for two consecutive days. Platelet recovery was defined as a platelet count of X20 Â 10 9 /l independent of platelet transfusions for at least 7 days. Whole blood WBC donor chimerism was performed using quantitative fluorescent-labeled variable number of tandem repeats (VNTR) utilizing loci D1580, D1757, D15111, and APO B-specific loci utilizing fluorescent-labeled oligonucleotide primers analyzed by Visible Genetics Open Gene System. 28 Subset chimerism of specific WBC subsets was not performed. HLA typing of donor and recipient was performed by low-resolution serology for class I (HLA A and B) and high-resolution DNA typing for class II (DRB1). Toxicity was graded according to the NCI Common Toxicity Criteria for bone marrow transplant recipients (CTC 2.0). 29 Acute and chronic GVHD were scored according to previously published guidelines. 30, 31 Probabilities of neutrophil recovery, platelet recovery, acute and chronic GVHD, regimen-related death (nonrelapse mortality), and survival were estimated using the Kaplan-Meier method. 32 Poor-risk patients were defined as patients with malignant disease with progressive disease (PD) and/or third complete remission (CR3). The remainder of the patients had good-risk disease status.
Statistics
Results are presented as medians with specified ranges of data sets. The probability of overall survival at 1 year was calculated using the Kaplan-Meier method performed with the Prism s statistical program (Graph Pad, San Diego, CA, USA).
Results
Patient demographics and disease status
From June 2001 to May 2003, 21 patients with either malignant or nonmalignant diseases received reduced RI AlloSCT (MFD or unrelated cord blood) at the Children's Hospital of New York-Presbyterian. Characteristics of the patients are summarized in Table 1 . Patients with malignant disease were evaluated for disease status immediately prior to RI AlloSCT. Nonmalignant disease patients were transfusion dependent due to their underlying hematological abnormalities. The median age was 13 (0.5-21) years. The gender distribution was 13 males and eight females. The disease distribution was as follows: six patients with Hodgkin's disease -three patients were in second complete remission (CR), one patient was in partial remission (PR), and two patients had progressive disease (PD); one patient with non-Hodgkin's lymphoma (anaplastic large cell lymphoma) in PR; two patients with neuroblastoma -one in CR and one with PD; one patient with Wilms' tumor with PD; one patient with chronic myelogenous leukemia (CML) in chronic phase (CP); one patient with acute myeloblastic leukemia (AML) in first CR; two patients with myelodysplastic syndrome (MDS) in refractory anemia stage; one patient with Wiskott-Aldrich syndrome with stable disease (SD); two patients with bthalassemia major with SD; two patients with severe aplastic anemia with SD; one patient with group 1 Fanconi anemia; 33 and one patient with hemophagocytic lymphohistiocytosis (HLH).
Allogeneic stem cell donors and cord blood units
Patients received transplants from either MFDs (seven) or unrelated cord blood units (UCB) (14) ( Table 1) . There were five 6/6 and two 5/6 matches in the MFD recipients and 10 4/6 and four 5/6 matches in the UCB recipients. All mismatches were at class I. For MFD, the median nucleated cell dose was 8.3 Â 10 8 cells/kg (4.7-18.9) and the median CD34 dose was 5.0 Â 10 6 cells/kg (4.6-6.4). For UCB, the median nucleated cell dose was 4.3 Â 10 7 cells/kg (0.9-10.8) and the median CD34 dose/kg was 1.9 Â 10 5 cells/kg (0.3-6.9) ( Table 1) .
Hematologic reconstitution following RI AlloSCT
Myeloid engraftment was defined as achievement of a peripheral blood ANC of X500/mm 3 for 2 consecutive days after nadir. Platelet engraftment was defined as achievement of a platelet count of X20 000/mm 3 for 7 consecutive days without need for platelet transfusion after nadir (if any) ( Table 2 ). Three patients were censored for myeloid recovery (autologous reconstitution) and seven patients were censored for platelet recovery (two deaths, four autologous reconstitution, and one patient with no evidence of platelet engraftment 111 days post transplant despite sustained myeloid engraftment). The median time to myeloid engraftment was 14.5 days (2-45) (Figure 1a ) and the median time for platelet engraftment was 21 days (6-170) (Figure 1b) . UCB patients had a median time to myeloid engraftment of 18 days (2-45) and platelet engraftment of 31 days (6-170), while MFD patients' median time to myeloid engraftment was 14 days (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) and platelet engraftment was 11 days (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) .
Sequential increments in myeloid donor chimerism
For the 18 patients who showed evidence of allogeneic engraftment, the myeloid donor chimerism results were recorded at different post transplant time points Table 2 Hematological reconstitution, GVHD, mixed donor chimerism, and outcome Reduced intensity AlloSCT in pediatric recipients G Del Toro et al (days þ 30, þ 60, þ 100) ( Figure 2 ). Three of the 18 patients did not survive to day 100. A maximal donor chimerism was also recorded. At day 30, the mean percentage of mixed donor chimerism was 82.278%. By day 60, it had increased to 92.974.2%, and was 90.975.7% on day 100.
Patient
Maximal donor chimerism
Maximal donor chimerism results for MFD recipients were 100% for four peripheral blood stem cell recipients and 55 and 65% for two bone marrow recipients. The MFD recipient who received both bone marrow and peripheral blood stem cells from his sibling donor achieved 100% donor chimerism. Maximal donor chimerism for UCB recipients was 100% for eight patients, 98% for one patient, 95% for one patient, and 55% for another patient who died on day þ 79 of PD (Table 2) . Three UCB recipients failed to engraft (primary graft failure) (b-thalassemia, MDS, HLH). Two of the patients who failed to engraft went on to receive a second allograft from a UCB donor unit following a full myeloablative transplant and achieved X95% donor chimerism with the second graft (time to mixed donor chimerism is depicted in Figure 2 ). There were two secondary graft failures, one with severe aplastic anemia following MFD BM and one with b-thalassemia following UCBT (see Table 2 ).
GVHD (acute and chronic)
Eight patients developed acute GVHD (AGVHD) and two patients developed chronic GVHD (CGVHD). Three patients developed grade III AGVHD. One patient developed extensive CGVHD ( Table 2) . Four of seven patients who received AlloSCT from MFD developed AGVHD, while five of 11 evaluable UCB recipients developed AGVHD. Figure 3a and b demonstrate the probability of developing acute and chronic GVHD, respectively. The probability of developing grades II-IV and III-IV AGVHD was 38 and 17%, respectively. The incidence of developing CGVHD was 0% at the median follow up of 149 days. However, the median follow-up is short to accurately determine the true incidence of CGVHD.
Grades 3 and 4 toxicities
Two patients developed grade 4 nonhematopoietic toxicity: one patient developed severe FK-506 leukoencephalopathy that was fatal (grade 4 neurotoxicity), one patient developed transient and reversible increase in liver function tests (AST/ALT) during busulfan administration (grade 4 hepatotoxicity) and this resolved after conditioning therapy was completed. Two patients developed self-limiting hemorrhagic cystitis (grade 3 hematuria). One patient developed grade 3 pancreatitis. Two patients developed grade 3 nausea and vomiting. Infectious complications included 21 bacterial sepsis (resolved), one systemic candidiasis (resolved), one candidal liver abscess (resolved), one candida pneumonitis (persistent), two gastrointestinal adenovirus (one persistent, one resolved), one pulmonary adenovirus (persistent), one disseminated adenovirus (resolved), one disseminated mycobacterium avium complex (persistent), one mycobacterum chelona systemic infection (resolved), two respiratory syncitial virus upper respiratory infections (resolved), four clostridium difficile colitis (resolved), one rotavirus gastroenteritis (persistent), two influenza B respiratory infections (one persistent, one resolved), two herpes simplex virus I oropharyngeal infections (resolved), one herpes zoster infection (resolved), one parainfluenza-3 infection (resolved), and one subclinical CMV infection.
Overall survival (OS)
The estimated 1-year OS for all patients is 72.9% (95% CI, 48.9-96.9%). The 1-year OS for good-risk patients (IBMTR criteria) is 88.9% (95% CI, 68.4-100%). The 1-year OS for poor-risk patients is 38.9% (95% CI, 0-94.5%) (Figure 4 ). Four patients have died. The causes of death were PD in three patients who had PD at study entry (Hodgkin's disease, Wilms' tumor, neuroblastoma), and one patient died of FK-506 neurotoxicity.
Discussion
Acute short-term toxicity, including infection and organ decompensation following myeloablative conditioning therapy, can result in a significant incidence of early mortality (day 30 to day 100). Recent results comparing RI conditioning with myeloablative conditioning followed by HLA-matched sibling AlloSCT have demonstrated a significant reduction in red blood cell and platelet transfusions, bacteremias from day 0 to day 30, and day 100 survival, respectively. 34, 35 More importantly, long-term late effects including growth retardation, [36] [37] [38] infertility, 36, [39] [40] [41] and secondary malignancies [42] [43] [44] [45] are major complications following myeloablative conditioning therapy, especially in vulnerable children who are more susceptible to these complications because of developing tissues and the 60-70 life years remaining after myeloablative conditioning therapy.
Despite a log less of CD34 þ /kg allogeneic stem cells (median 0.369 Â 10 greater mixed donor chimerism and one patient achieved 55% mixed donor chimerism by day þ 79 but died of PD. All patients in this study received a fludarabine-based RI conditioning with the addition of either busulfan, cyclophosphamide, or melphalan with or without rabbit ATG, alemtuzumab, or horse ATG. Comparative studies in adult RI AlloSCT recipients, either HLA-MFDs or HLAmatched unrelated adult donors, have utilized a variety of fludarabine-based RI conditioning regimens. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] 46, 47 In comparison to our current results, the above-mentioned studies utilized older patients, many with poor-risk or refractory hematological malignancies, and the majority had comorbid factors that prevented the use of full myeloablative SCT. The median recipient age in the majority of the adult RI AlloSCT studies was over 50 years of age. Our results in pediatric recipients of RI AlloSCT have demonstrated similar results with respect to donor chimerism and outcome to adult studies despite utilizing significantly reduced doses of CD34/kg stem cells.
More recently, RI AlloSCT using HLA-matched unrelated adult donors has also been demonstrated to be associated with the development of mixed donor chimerism. [19] [20] [21] 48, 49 These results suggest that RI conditioning with adequate mobilized unrelated PBSC from unrelated adult donors also results in a high degree of donor engraftment. However, these studies utilized a log higher dose of allogeneic CD34 progenitor cells/kg compared to our current study.
Barker et al 49 recently reported the results from the University of Minnesota of RI conditioning in adults with high-risk hematological malignancies and UCB grafts. In this study of 43 adult patients, 22 received 2 Gy TBI, fludarabine, and cyclophosphamide (50 mg/kg) and 21 patients received 2 Gy, fludarabine and busulfan (8 mg/ kg). The median CD34 dose/kg was 3.7 and 4.3 Â 10 5 /kg, respectively, in the two groups studied. In this study, Barker et al demonstrated similar results in adult recipients with two different RI conditioning regimens that resulted in 88-94% of patients achieving primary donor engraftment. Our results in the current study were comparable to the study by Barker et al, however, we utilized a TBI-based regimen in only one patient.
Hematological recovery in pediatric AlloSCT receiving RI conditioning in our study demonstrated a median time to myeloid engraftment of 14.5 days (2-45) and median time to platelet engraftment of 21 days (6-170). Most interesting was the subset analysis of recipients who received UCB grafts with a median nucleated cell dose of 4.3 Â 10 7 cells/kg (range 0.9-10.8) and RI conditioning. In this subgroup of pediatric recipients, the median time to myeloid engraftment was 18 days and to platelet engraftment was 31 days (6-170). In comparison, in previous UCBT studies utilizing myeloablative conditioning and similar UCBT nucleated cell dose/kg, the time to median myeloid recovery appeared to be similar to our results (range 15-25 days). 1, 4, 5, 7 However, the median time to platelet recovery X20 000/mm 3 first day untransfused Â 7 consecutive days was a median of 31 days (6-170) in our recipients receiving RI conditioning and UCBT. These results compare favorably and appear to be significantly improved compared to similar studies in children receiving myeloablative conditioning and similar doses of UCBT nucleated cells/kg. 1, 4, 5, 7 Future studies comparing platelet recovery between RI and full ablative conditioning and UCBT should focus on the number of infused megakaryocytic progenitor cells/kg (CD41 or CD61 and CFU-Meg) to determine if this improvement in platelet recovery is secondary to infusion of different doses of megakaryocytic progenitor cells or related to differences in host stromal toxicity between the two differing intensity conditioning regimens.
There were five episodes of graft failure in our study. The three primary and two secondary graft failures occurred in patients with b-Thalassemia, HLH, MDS, and SAA. These conditions may also be associated with graft failure following myeloablative AlloSCT. Future studies will be required to determine optimal conditioning regimens required for this subgroup of patients.
Despite the achievement of 450% donor chimerism in six children with progressive malignant disease, three patients eventually succumbed to PD after attaining mixed donor chimerism. One patient with very refractory Hodgkin's disease who had PD at the time of RI AlloSCT achieved 55% mixed donor chimerism after an UCB graft but ultimately died of PD on day þ 79. Similarly, two patients with solid tumors (Wilms' tumor and neuroblastoma) who had PD achieved 100% mixed donor chimerism but died of PD on days þ 90 and þ 193, respectively. These results are consistent with other RI conditioning AlloSCT studies in adults with poor-risk and/or refractory solid tumors. [50] [51] [52] Carella et al 53 reported an alternative approach of first utilizing myeloablative conditioning therapy and autologous SCT followed by a RI fludarabine-based regimen and HLA-matched sibling donor AlloSCT in 15 patients with advanced and resistant Hodgkin's disease and non-Hodgkin's lymphoma. After the myeloablative conditioning and AutoSCT, three patients obtained a CR and the remainder (12) a partial response. However, following RI AlloSCT, 11 patients obtained a CR, one patient a partial response, and three patients developed PD. This study suggests that patients with refractory hematological malignancies require the induction of a partial response, particularly patients with poor-risk lymphomas, prior to benefiting from RI conditioning and AlloSCT. Similarly, in children with refractory or progressive solid tumors and/or lymphomas, RI AlloSCT is not likely to result in any significant enhancement of the graft vs tumor effect. This approach of RI AlloSCT will likely be of most potential benefit in children with malignancies earlier in their disease process, particularly in those children obtaining a complete or partial response with alternative therapy prior to RI AlloSCT.
Previous adult studies utilizing RI conditioning therapy and AlloSCT have been focused on patients with significant comorbidity who otherwise would be ineligible for a myeloablative AlloSCT. While a small number of children will also likely have significant comorbid factors, which would make them ineligible to receive a myeloablative AlloSCT, the majority of children do not present with these types of comorbidities. However, children have 60-70 life years remaining after myeloablative AlloSCT and are at risk for significant long-term late effects. Socie´et al 54 recently reported long-term survival and late effects after allogeneic bone marrow transplantation in 6691 patients who were free of their original disease for at least 2 years after AlloSCT. While the largest percentage of late deaths in this large cohort were related to relapse of original disease (46%), a large number of patients died of other secondary complications including GVHD (31%), infection (6%), secondary malignancies (6%), and organ failure (6%). Children with nonmalignant disease who require myeloablative therapy and AlloSCT for curative intent fear the above-mentioned long-term late complications associated with this therapy, including growth failure, gonadal failure, secondary malignancies, and secondary MDS. Furthermore, in children with hematological malignancies previously curable with myeloablative therapy and Allo-SCT, these above-mentioned risks of secondary complications weigh heavily on their decision to proceed with curative-intent therapy. It remains to be determined whether a select group of children receiving RI conditioning therapy and AlloSCT will benefit from both a reduced risk of disease reoccurrence and at the same time a reduced risk of long-term lethal complications. A randomized study with long-term follow-up will be required to answer these questions.
In summary, we have demonstrated in this pilot study to successfully induce a high degree of mixed donor chimerism and myeloid engraftment in children with both malignant and nonmalignant disease following RI conditioning therapy with either a matched family donor or UCB donor AlloSCT. Over 80% of patients fully engrafted with 450% mixed donor chimerism despite a very low dose of CD34 cells/kg, especially in the unrelated cord blood transplant recipients. These results, however, include a heterogenous group of patients with different donor sources and three different RI conditioning regimens. These preliminary results should be interpreted with caution until larger groups of children with a homogenous diagnosis, cell source, and RI regimen are utilized. Additionally, longer follow-up is required to more accurately assess chronic GVHD and survival. It remains to be determined what degree of intensity is required for different pediatric subpopulations. Patients with primary refractory hematological disease, including hemoglobinopathies, MDS, HLH, and/or severe aplastic anemia, may require more intense nonmyeloablative conditioning compared to patients who have malignant disease who have previously received chemo and/or immunotherapy and/or myeloablative autologous SCT and who may require less-intensive RI conditioning. It is also unclear at what point in the disease course that RI conditioning should be incorporated in children with either malignant or nonmalignant diseases. Future studies should also investigate subset donor chimerisms, particularly T-cell, monocyte, and red cell chimerism in pediatric recipients with malignant and nonmalignant diseases, respectively. The role of graft vs tumor effect following RI AlloSCT in children with advanced malignancies needs further investigation. Lastly, to more accurately determine the difference, if any, of late long-term effects in pediatric recipients following RI AlloSCT requires a larger cohort of patients and with much longer follow-up.
